The date for UK Kidney Week 2024 abstracts submission will be announced in November 2023
By submitting an abstract, you agree to the following:
The abstract is scientifically sound and ethically approved.
The abstract is not an advertisement, nor contains anything obscene, defamatory, libellous, unlawful or in any way actionable.
The abstract will be included on the online conference portal and will be made available on the UK Kidney Week website.
All authors have seen and approved the abstract as submitted.
The work has not previously been accepted for publication in a journal.
Guidelines for abstract submission:
Word count: maximum 50
The ‘Full title’ should be presented sentence case (not in title case or block capitals), i.e. only the first letter of the title or appropriate terms such as abbreviations or proper nouns should be upper case.
The title of the abstract should encompass the hypothesis you are testing or the nature of your investigation.
Please do not include author details or information that identifies your unit or hospital in the abstract title.
Authors and Affiliations
You will be asked to provide author and affiliation details within the submission process.
You will be asked to choose the relevant topic for your abstract.
Word count: Maximum 200
You will be asked to provide a short biography for the lead author.
Word count: Maximum 500
Please do not include author details or information that identifies your unit or hospital in the body of the abstract.
The abstract should follow this format:
The first paragraph should concisely outline the background to the research and why the research needed to be undertaken – hypothesis testing or lack of data in a certain area.
The second paragraph should detail the methods you have used to generate your data. Full details of non-standard abbreviations should be given the first time it is used.
Methods should flow from the most important/widely used method to the least.
The next section requires clear expression of your results. Quantitative data should always be included with the associated unit of measurement (e.g. ng/ml, % of control), where possible. The use of the word ‘significant’ should only be used in association with data that has been assessed for significance, with P<0.05, using an appropriate statistical test. The nature of the test can be outlined in the poster/oral. A figure or table may be included (see below).
The final section should concisely outline your main findings, either in the form of a summary or a conclusion. Please refrain from stating that further research is necessary.
It is best to type your abstract straight into the online submission form, or alternatively paste the text from a word-processed document.
Tables, figures and references
Tables, figures and references may be included with your abstract.
Submitting your abstract
If all required abstract submission fields have been completed, you will have the option to submit your abstract at the bottom of the page. If there are any remaining fields or sections to complete you will only have the option to save your submission as a draft until they are completed.
Once you click the 'submit' button, the online submission page will change to a submission confirmation page and you will receive a confirmation email. This may get sent to your junk/spam folder but if you do not receive it, please email firstname.lastname@example.org.
You will be able to log back in and edit your submitted abstract until submission closes.
Abstract selection will be the responsibility of the Programme Committee and the submitting author of each abstract will be contacted via the email address given on the submission (unless a different email address is provided).
Case report abstracts
UKKW will accept case report abstracts for consideration for poster presentation. Case reports that are based on clinic-pathological (kidney biopsy) findings will be eligible for inclusion in the clinic-pathological conference session.
Case Reports should show one or more of the following:
unexpected or unusual disease presentations
unreported or unusual side effects
patient safety considerations
findings of relevance to pathogenesis
unusual events during treatment or follow-up
presentation and management of very rare diseases.
Reports can also comprise:
N of 1 trials
meta-analyses of published case reports
retrospective studies that include case-specific information (age, sex and ethnicity)